Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
09 February 2024 - 6:00PM
UK Regulatory
Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL
REPORT
HBC had gross operating revenues of NOK 47.4m (33.6m) in the
fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted
for the sale of assets in the second quarter, operating revenues
were NOK 194.9m for the full year, representing an increase
compared to 2022 of 38 percent.
Cash and cash equivalents increased by NOK 6.2m during the
quarter, leaving total holding at NOK 23.9m at the end of the year,
compared to NOK 32.4m at the end of 2022. Including credit
facilities, HBC had NOK 62.5m in free liquidity as of the end of
2023.
Jon Olav Ødegård, CEO of HBC says: “I am pleased to point
out the investment in HBC through a new class of preference shares,
settled by converting NOK 144 million of debt, demonstrates our
commitment to financial stability and growth. We closed the
transaction in early January 2024, resulting in a strong financial
position for HBC. Our targets for 2024 have been set and this will
be another exciting year where we aim for 50 % further growth in
sales and a higher capacity utilization to deliver positive EBITDA
in 2024.”
Highlights in the fourth quarter
- HBC continued its sales trend in the fourth quarter at a higher
level than earlier years. Sales revenues were 46 million NOK in the
quarter, up 26 percent compared to fourth quarter 2022. HBC has
made a significant jump from previous years, with total sales
revenues for the year at 190 million, up 58 per cent, an increase
of 70 million from 2022. The sales successes are a result of
systematic promotion in international markets of our unique, fresh
ingredients founded on science and circular economy, that has
enabled us to enter high value human and pet markets.
- The gross margin in the fourth quarter is negatively impacted
by an extraordinary write-down of 15 million NOK of our excess
calcium inventory. Despite this, the trend for new projects is
accelerating with several new product launches for CalGo and new
pet buyer in the quarter. Gross margins excluding the write-down
was at 27 percent compared to 18 percent fourth quarter 2022.
- R&D work on all our ingredients continued unabated and with
new significant results already completed, the outlook for new
projects continues to gather pace as a result. Scientific
validation is crucial to differentiate and create credibility in a
competitive market for new consumer health products.
- At the end of the fourth quarter HBC entered into an agreement
with Hofseth International to make an investment in HBC in a new
class of preference shares settled by converting 144 million NOK of
accumulated accounts payables. The effect of the transaction
boosted our equity ratio in January.
Highlights after the quarter
- The transaction converting accounts payables to newly issued
preference B-shares was concluded and registered first week of
January 2024. The equity ratio of HBC consequently improved to
approximately 47 percent. Details of the transaction can be found
in the press release and call for general meeting.
Please find the HBC Q4 & Full year 2023 Financial report
attached.
For further information, please contact:
Christel Elise Kanli, CFO of Hofseth BioCare ASA
Phone: +47 41623188
E-mail: ck@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier
and an incubator for new pharmaceutical drug leads. Research is
ongoing to identify the individual elements within its ingredients
that modulate inflammation and the immune response with
pre-clinical studies ongoing in multiple clinics and university
research labs. Lead clinical and pre-clinical candidates are
focused on developing an oral treatment for inflammatory disease
driven by eosinophils (a type of white blood cell). Clinical trial
work with the oil is ongoing to ameliorate lung inflammation in
eosinophilic asthma and COPD ("smokers lung").
Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative
colitis and the orphan condition necrotizing enterocolitis) and
using peptide fractions of salmon protein hydrolysate (SPH also
known as 'ProGo') as a Medical Food to help treat age-related
Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability,
optimal utilization of natural resources and full traceability.
Through an innovative hydrolysis technology, HBC can preserve the
quality of the lipids, proteins and calcium from fresh salmon
off-cuts.
Hofseth BioCare's headquarters are in Ålesund, Norway with
offices in Oslo, London, Zürich, New Jersey and Palo Alto, CA.
This information is subject to the disclosure requirements
pursuant to Section 5-12 of the Norwegian Securities Trading
Act
- HBC Q4 2023 Financial Report
Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart
From Nov 2024 to Dec 2024
Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart
From Dec 2023 to Dec 2024